| Literature DB >> 33895190 |
Arun Samidurai1, Lei Xi1, Anindita Das1, Audra N Iness1, Navin G Vigneshwar1, Pin-Lan Li2, Dinender K Singla3, Sakthivel Muniyan4, Surinder K Batra4, Rakesh C Kukreja5.
Abstract
Cyclic nucleotide phosphodiesterases (PDEs) are superfamily of enzymes that regulate the spatial and temporal relationship of second messenger signaling in the cellular system. Among the 11 different families of PDEs, phosphodiesterase 1 (PDE1) sub-family of enzymes hydrolyze both 3',5'-cyclic adenosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP) in a mutually competitive manner. The catalytic activity of PDE1 is stimulated by their binding to Ca2+/calmodulin (CaM), resulting in the integration of Ca2+ and cyclic nucleotide-mediated signaling in various diseases. The PDE1 family includes three subtypes, PDE1A, PDE1B and PDE1C, which differ for their relative affinities for cAMP and cGMP. These isoforms are differentially expressed throughout the body, including the cardiovascular, central nervous system and other organs. Thus, PDE1 enzymes play a critical role in the pathophysiology of diseases through the fundamental regulation of cAMP and cGMP signaling. This comprehensive review provides the current research on PDE1 and its potential utility as a therapeutic target in diseases including the cardiovascular, pulmonary, metabolic, neurocognitive, renal, cancers and possibly others.Entities:
Keywords: Cardiac hypertrophy; Metabolic syndrome; Phosphodiesterase; Pulmonary arterial hypertension; cAMP; cGMP
Mesh：
Substances：
Year: 2021 PMID： 33895190 PMCID： PMC8815087 DOI： 10.1016/j.pharmthera.2021.107858
Source DB: PubMed Journal: Pharmacol Ther ISSN： 0163-7258 Impact factor: 13.400